Search

Coloplast A-S (Class B)

Fechado

481.8 -2.55

Visão Geral

Variação de preço das ações

24h

Atual

Mín

480

Máximo

494.4

Indicadores-chave

By Trading Economics

Rendimento

70M

875M

Vendas

2M

7B

P/E

Médio do Setor

32.582

84.243

EPS

3.88

Rendimento de Dividendos

4.29

Margem de lucro

12.572

Funcionários

16,744

EBITDA

2B

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.86% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.29%

2.28%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4B

119B

Abertura anterior

484.35

Fecho anterior

481.8

Coloplast A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de fev. de 2026, 23:57 UTC

Conversa de Mercado

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 de fev. de 2026, 23:47 UTC

Conversa de Mercado

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 de fev. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 de fev. de 2026, 23:34 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de fev. de 2026, 23:34 UTC

Conversa de Mercado

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 de fev. de 2026, 23:26 UTC

Conversa de Mercado

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 de fev. de 2026, 22:55 UTC

Ganhos

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 de fev. de 2026, 22:55 UTC

Ganhos

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 de fev. de 2026, 22:55 UTC

Ganhos

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 de fev. de 2026, 22:55 UTC

Ganhos

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 de fev. de 2026, 22:55 UTC

Ganhos

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 de fev. de 2026, 22:55 UTC

Ganhos

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 de fev. de 2026, 21:43 UTC

Conversa de Mercado

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 de fev. de 2026, 21:16 UTC

Conversa de Mercado

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 de fev. de 2026, 21:15 UTC

Conversa de Mercado

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 de fev. de 2026, 09:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

7 de fev. de 2026, 09:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

7 de fev. de 2026, 05:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

7 de fev. de 2026, 02:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Big Money, High Anxiety -- Barrons.com

6 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

6 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

6 de fev. de 2026, 21:40 UTC

Aquisições, Fusões, Aquisições de Empresas

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 de fev. de 2026, 21:22 UTC

Conversa de Mercado

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 de fev. de 2026, 21:17 UTC

Ganhos

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 de fev. de 2026, 21:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

6 de fev. de 2026, 21:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 de fev. de 2026, 21:13 UTC

Ganhos

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 de fev. de 2026, 21:13 UTC

Ganhos

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 de fev. de 2026, 21:04 UTC

Conversa de Mercado

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 de fev. de 2026, 20:34 UTC

Ganhos

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Coloplast A-S (Class B) Previsão

Preço-alvo

By TipRanks

11.86% parte superior

Previsão para 12 meses

Média 901.38 DKK  11.86%

Máximo 1,056 DKK

Mínimo 720 DKK

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para Coloplast A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

8 ratings

2

Comprar

4

Manter

2

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat